Community Health Center Pharmacy Models Explained: In-House, Contract, or Hybrid

Every community health center pharmacy decision comes down to one question: do you own the dispensing, rent it, or both? The answer shapes your capital requirements, your staffing model, your compliance surface, and how exposed you are to manufacturer restrictions on 340B contract pharmacy access. There is no universally correct structure. There is a correct structure for your patient volume, your payer mix, your geography, and your appetite for running what is, operationally, a retail business.

This guide compares the three models an FQHC or community health center can use - entity-owned, contract pharmacy, and hybrid - and what each one actually costs you in effort.

What is a 340B pharmacy?

A 340B pharmacy is any pharmacy that dispenses outpatient drugs purchased at 340B ceiling prices by a covered entity registered with HRSA. It can be a pharmacy the covered entity owns and operates, or an outside retail pharmacy that dispenses on the entity's behalf under a written contract pharmacy agreement. Strictly speaking, the pharmacy is not "in the program" - the covered entity is, and the pharmacy dispenses under the entity's registration and remains the entity's compliance responsibility.

Who qualifies for the 340B program?

Eligibility is set by statute, not by application merit. Section 340B of the Public Health Service Act lists the eligible categories: federally qualified health centers and FQHC look-alikes funded or designated under Section 330, Ryan White clinics, certain federally funded specialized clinics, and several hospital categories.

For health centers, the practical FQHC requirements are easy to state and harder to maintain: current Section 330 grant funding or look-alike designation, registration in the 340B Office of Pharmacy Affairs Information System (OPAIS) during a quarterly registration window, accurate listing of every service site you intend to use, and annual recertification. Each service site must be within your HRSA-approved scope of project - listed on your Form 5B and Notice of Award - before it can be registered as a 340B child site. The Medicare cost report standard that gets discussed in 340B circles applies to hospital covered entities, not to grantees like health centers. Check HRSA's published windows and requirements directly rather than relying on secondhand summaries.

The three models at a glance

Model 1: the entity-owned pharmacy

An entity-owned pharmacy is a pharmacy your health center licenses, staffs, and operates. You purchase 340B drugs directly into your own inventory and dispense them to your own patients.

What it requires. A state board of pharmacy license, DEA registration, an NCPDP number, a pharmacy management system, a 340B split-billing or inventory management platform, PBM and payer contracting, a pharmacist-in-charge and support staff, and physical space that meets state requirements. Payer contracting is routinely the step health centers underestimate - network enrollment can take months and some networks are closed.

What it gives you. Direct control of the dispense, the patient conversation, and the 340B accumulation logic. No per-script dispensing fee to a third party. Adherence programs, medication synchronization, and clinical pharmacy services become far easier to run when the pharmacist sits inside your care team. And because most manufacturer 340B restrictions have targeted contract pharmacy distribution rather than shipments to covered entity locations, an in-house pharmacy is generally the more insulated channel.

What it costs you. Fixed overhead that does not flex with volume. A pharmacy that dispenses 150 scripts a day and a pharmacy that dispenses 40 both need a pharmacist on duty. Below a certain volume, the model does not carry itself - which is the central question to model honestly before committing.

Model 2: 340B contract pharmacy arrangements

Under a 340B contract pharmacy arrangement, an outside pharmacy dispenses to your patients on your behalf under a written agreement, and the arrangement is registered in OPAIS. Most arrangements run on a replenishment model: the pharmacy dispenses from its own stock, a third-party administrator identifies eligible dispenses, and 340B inventory is ordered to replenish what was used.

What it requires. A written contract that reflects HRSA's recommended terms, OPAIS registration of the arrangement, a TPA, and - the part that gets skipped - an actual oversight program. Monthly reconciliation of dispensing data against your eligibility file, periodic self-audits of the contract pharmacy channel, and documented review of TPA output.

What it gives you. Speed, reach, and near-zero capital outlay. For a health center with dispersed sites or a rural service area, contract pharmacies extend access in ways an in-house pharmacy cannot.

What it costs you. Margin, through dispensing fees and TPA fees, and control. You are relying on a partner's data and a partner's process. As we cover in Navigating the Challenges of 340B Pharmacies, a contract pharmacy network that is set up and then left alone reliably becomes a compliance liability.

Model 3: hybrid

In our experience, hybrid is where many maturing health centers land. An entity-owned pharmacy at the flagship site captures the highest-value scripts and anchors clinical pharmacy services. Contract pharmacies cover satellite sites, after-hours fills, specialty categories you cannot stock, and patients who live nowhere near a clinic.

The tradeoff is complexity. Two channels means two sets of accumulation logic, two reconciliation processes, and a routing decision for every prescription. Your 340B management program needs a written channel policy - which prescriptions go where, and why - because an auditor will ask.

Where the 340B rules land differently by model

The GPO prohibition

The 340B statute's group purchasing organization prohibition applies to disproportionate share hospitals, children's hospitals, and free-standing cancer hospitals. It does not apply to FQHCs, critical access hospitals, sole community hospitals, or rural referral centers. For a community health center standing up an in-house pharmacy, that is a meaningful planning advantage: you can use GPO pricing for non-340B outpatient purchases without triggering the prohibition. The GPO prohibition and its entity-type exclusions are set by statute, not by guidance. Confirm your registered entity type in OPAIS and review the statutory text with counsel before relying on this in a purchasing decision.

Medicaid duplicate discounts and the carve-in or carve-out decision

The statute prohibits a manufacturer from having to provide both a 340B discount and a Medicaid rebate on the same drug. Your carve-in or carve-out decision for Medicaid fee-for-service is recorded in the Medicaid Exclusion File, and it must match what you actually do. Managed Medicaid is handled outside the MEF and varies by state and plan.

This gets harder in a hybrid model, and the channel matters. HRSA's contract pharmacy guidance provides that covered entities should not dispense 340B drugs to Medicaid fee-for-service patients through contract pharmacies unless the entity, the pharmacy, and the state Medicaid agency have an arrangement in place to prevent duplicate discounts, with HRSA notified. In practice most health centers carve out Medicaid fee-for-service in the contract pharmacy channel even where they carve in at an owned pharmacy. Confirm your approach against current HRSA guidance and your state's Medicaid rules before setting channel policy.

The patient definition

The 340B patient definition governs who you may dispense to under the program, and it is the source of a large share of audit findings. It rests on HRSA guidance rather than notice-and-comment regulation - HRSA's proposed 2015 "mega-guidance" was withdrawn in 2017, and subsequent litigation has added interpretive uncertainty. Write a policy that tracks the current HRSA guidance, apply it identically in every channel, and get entity-specific questions in front of counsel. Our HRSA audit prep checklist for FQHCs walks through how auditors test this.

How to choose

Work the decision in this order.

1. Start with script volume in your own patient panel. Model realistic capture, not total prescriptions written. An in-house pharmacy only works if enough of your patients will actually fill with you.
2. Check manufacturer policies for your top drug categories. If your savings model depends heavily on drugs with restrictive contract pharmacy policies, that changes the calculus toward in-house.
3. Map your geography. Multiple sites across a wide area push toward contract or hybrid regardless of volume.
4. Price the compliance overhead honestly. Contract pharmacy is not "set and forget." Budget for TPA oversight, reconciliation, and self-audits - a well-run TPA relationship is a staffed function, not a line item.
5. Sequence it. Many health centers start with contract pharmacy, build volume and data, then open an in-house pharmacy once the numbers support it. That path is usually lower risk than the reverse.

The honest summary

No model is safer by default. An in-house pharmacy concentrates risk in operations and capital. Contract pharmacy concentrates it in vendor oversight and manufacturer policy. Hybrid spreads both and adds coordination cost. What separates health centers that run pharmacy well from those that struggle is not the model they picked - it is whether they staffed the compliance function that model requires. Model the decision against your own script data before you commit, and work from HRSA and Apexus guidance for the regulatory specifics.